We are pleased to announce the successful launch of the Iraqi Pharmaceutical Industry Company conference. With a notable attendance of 90% of healthcare providers, the conference provided a platform to discuss our company's commitment to producing oncology and hematology medications of exceptional quality at a cost that remains accessible. Emphasis was placed on our rigorous adherence to professional standards and the significance of conducting bioequivalence studies at FDA-approved facilities, situated outside of Iraq.
During the conference, constructive dialogues led to the establishment of a promising long-term partnership aimed at enhancing the healthcare landscape in Iraq. This agreement underscores our collective dedication to advancing healthcare standards and ensuring the availability of essential medications to those in need.
https://www.instagram.com/reel/C5IpxZjh5Bx/?igsh=MXY4NWhtejMxNWpldg==
